We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Inimex and SARomics Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration
News

Inimex and SARomics Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration

Inimex and SARomics Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration
News

Inimex and SARomics Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inimex and SARomics Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inimex Pharmaceuticals and SARomics Biostructures have announced that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex’s Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain.

The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.

The p62 ZZ domain was cloned, expressed, purified and crystallized by SARomics Biostructures in collaboration with their molecular biology partner Vectron Biosolutions in Trondheim, Norway. Excellent crystallographic data were obtained at the MAX-lab synchrotron in Lund, Sweden.

“We are very excited to be able to help Inimex Pharmaceuticals fully leverage the potential of IMX942 by revealing the molecular details of its interactions with its target protein”, says Dr. Derek Logan, Chief Scientific Officer of SARomics Biostructures AB.
Advertisement